Callitas Theraputics Inc., a wholly owned subsidiary of Callitas Health Inc.

C-103 & Orlistat Companion

C-103 & Orlistat Companion 2017-07-31T14:07:56+00:00

Project Description

< BACK TO OUR PATENTS

The patents used in C-103, a reformulation of Orlistat that helps minimize and reduce the negative side effects of the popular weight loss drug.

US Patent 7,662,373: “Method and composition of a medicament to decrease the adverse events of Orlistat, an oral lipase inhibitor”

US Patent 8,110,186: “Method to maintain the efficacy of Orlistat”

US Patent Application 15/279,773: “Dual Compartment Capsule for the Administration of Orlistat”

ABOUT CALLITAS

As a company, our number one goal is helping people by bringing products to market that improve quality of life. All our drug treatments and biomedical technologies fit our mission to deliver breakthrough products and services that reduce invasiveness and enhance daily living.

INVESTOR INQUIRIES

  • 1.859.868.3131
  • investors@callitas.com

  • 187 Pavilion Parkway
    Suite 200
    Newport, Kentucky 41071

PRESS AND MEDIA INQUIRIES

  • pressroom@callitas.com

PRODUCT INQUIRIES